

# Filipa Mascarenhas-Melo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7557323/publications.pdf>

Version: 2024-02-01

17  
papers

642  
citations

758635

12  
h-index

940134

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1049  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat). <i>Experimental Diabetes Research</i> , 2011, 2011, 1-12.	3.8	128
2	Plant-mediated green synthesis of metal-based nanoparticles for dermopharmaceutical and cosmetic applications. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120311.	2.6	104
3	Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations. <i>Pharmaceutical Research</i> , 2021, 38, 947-970.	1.7	74
4	Diabetes abrogates sex differences and aggravates cardiometabolic risk in postmenopausal women. <i>Cardiovascular Diabetology</i> , 2013, 12, 61.	2.7	56
5	New Markers of Early Cardiovascular Risk in Multiple Sclerosis Patients: Oxidized-LDL Correlates with Clinical Staging. <i>Disease Markers</i> , 2013, 34, 341-348.	0.6	56
6	Differential Effects of Acute (Extenuating) and Chronic (Training) Exercise on Inflammation and Oxidative Stress Status in an Animal Model of Type 2 Diabetes Mellitus. <i>Mediators of Inflammation</i> , 2011, 2011, 1-8.	1.4	38
7	Markers of Increased Cardiovascular Risk in Postmenopausal Women: Focus on Oxidized-LDL and HDL Subpopulations. <i>Disease Markers</i> , 2013, 35, 85-96.	0.6	32
8	New markers of early cardiovascular risk in multiple sclerosis patients: oxidized-LDL correlates with clinical staging. <i>Disease Markers</i> , 2013, 34, 341-8.	0.6	27
9	Endocannabinoid system in cardiovascular disorders - new pharmacotherapeutic opportunities. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2011, 3, 350.	0.2	24
10	Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	1.4	21
11	Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis. <i>International Journal of Pharmaceutics</i> , 2022, 618, 121656.	2.6	18
12	Nanocarriers for the topical treatment of psoriasis - pathophysiology, conventional treatments, nanotechnology, regulatory and toxicology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 95-107.	2.0	17
13	Main Determinants of PON1 Activity in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2012, 36, 317-323.	1.4	16
14	The Relationship between Nutritional Status and Functional Capacity: A Contribution Study in Institutionalised Portuguese Older Adults. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 3789.	1.2	8
15	Nanotechnology-based formulations toward the improved topical delivery of anti-acne active ingredients. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 1435-1454.	2.4	8
16	Application of nanotechnology in management and treatment of diabetic wounds. <i>Journal of Drug Targeting</i> , 0, , 1-21.	2.1	8
17	Emergent Biomarkers of Residual Cardiovascular Risk in Patients with Low HDL-c and/or High Triglycerides and Average LDL-c Concentrations: Focus on HDL Subpopulations, Oxidized LDL, Adiponectin, and Uric Acid. <i>Scientific World Journal</i> , The, 2013, 2013, 1-16.	0.8	7